177 related articles for article (PubMed ID: 37482043)
21. Durvalumab for recurrent or metastatic head and neck squamous cell carcinoma: Results from a single-arm, phase II study in patients with ≥25% tumour cell PD-L1 expression who have progressed on platinum-based chemotherapy.
Zandberg DP; Algazi AP; Jimeno A; Good JS; Fayette J; Bouganim N; Ready NE; Clement PM; Even C; Jang RW; Wong S; Keilholz U; Gilbert J; Fenton M; Braña I; Henry S; Remenar E; Papai Z; Siu LL; Jarkowski A; Armstrong JM; Asubonteng K; Fan J; Melillo G; Mesía R
Eur J Cancer; 2019 Jan; 107():142-152. PubMed ID: 30576970
[TBL] [Abstract][Full Text] [Related]
22. Neurons upregulate PD-L1 via IFN/STAT1/IRF1 to alleviate damage by CD8
Wang Y; Shen Y; Liang J; Wang S; Huang Y; Zhu Q; Zhang X; Yu K; Tong G; Yang C; Li Y; Wang J; Zhao Y
J Neuroinflammation; 2024 May; 21(1):119. PubMed ID: 38715061
[TBL] [Abstract][Full Text] [Related]
23. PD-L1 expression correlates with tumor-infiltrating lymphocytes and better prognosis in patients with HPV-negative head and neck squamous cell carcinomas.
Sanchez-Canteli M; Granda-Díaz R; Del Rio-Ibisate N; Allonca E; López-Alvarez F; Agorreta J; Garmendia I; Montuenga LM; García-Pedrero JM; Rodrigo JP
Cancer Immunol Immunother; 2020 Oct; 69(10):2089-2100. PubMed ID: 32448984
[TBL] [Abstract][Full Text] [Related]
24. The Regulation of Lymph Node Pre-Metastatic Niche Formation in Head and Neck Squamous Cell Carcinoma.
Hu C; Huang Q; Sun Q
Front Oncol; 2022; 12():852611. PubMed ID: 35574333
[TBL] [Abstract][Full Text] [Related]
25. Immunosuppressive effect of small extracellular vesicle PD-L1 is restricted by co-expression of CD80.
Liu JY; Yu ZL; Fu QY; Zhang LZ; Li JB; Wu M; Liu B; Chen G
Br J Cancer; 2023 Oct; 129(6):925-934. PubMed ID: 37532831
[TBL] [Abstract][Full Text] [Related]
26. The let-7 family of microRNAs suppresses immune evasion in head and neck squamous cell carcinoma by promoting PD-L1 degradation.
Yu D; Liu X; Han G; Liu Y; Zhao X; Wang D; Bian X; Gu T; Wen L
Cell Commun Signal; 2019 Dec; 17(1):173. PubMed ID: 31881947
[TBL] [Abstract][Full Text] [Related]
27. Programmed cell death ligand-1 and cytotoxic T cell infiltrates in metastatic cutaneous squamous cell carcinoma of the head and neck.
Kraft S; Gadkaree SK; Deschler DG; Lin DT; Hoang MP; Emerick KS
Head Neck; 2020 Nov; 42(11):3226-3234. PubMed ID: 32738025
[TBL] [Abstract][Full Text] [Related]
28. Protein kinase D3 regulates the expression of the immunosuppressive protein, PD‑L1, through STAT1/STAT3 signaling.
Cui B; Chen J; Luo M; Wang L; Chen H; Kang Y; Wang J; Zhou X; Feng Y; Zhang P
Int J Oncol; 2020 Apr; 56(4):909-920. PubMed ID: 32319563
[TBL] [Abstract][Full Text] [Related]
29. Genome-wide open reading frame profiling identifies fibroblast growth factor signaling as a driver of PD-L1 expression in head and neck squamous cell carcinoma.
Mann JE; Smith JD; Kulkarni A; Foltin SK; Scheftz EB; Murray IR; Gensterblum-Miller E; Brummel CV; Bhangale A; Hoesli RC; Brenner JC
Oral Oncol; 2023 Nov; 146():106562. PubMed ID: 37666053
[TBL] [Abstract][Full Text] [Related]
30. Regulation of programmed-death ligand in the human head and neck squamous cell carcinoma microenvironment is mediated through matrix metalloproteinase-mediated proteolytic cleavage.
Hira-Miyazawa M; Nakamura H; Hirai M; Kobayashi Y; Kitahara H; Bou-Gharios G; Kawashiri S
Int J Oncol; 2018 Feb; 52(2):379-388. PubMed ID: 29345283
[TBL] [Abstract][Full Text] [Related]
31. Preliminary Extracellular Vesicle Profiling in Drainage Fluid After Neck Dissection in OSCC.
Wang J; Man QW; Fu QY; Zhong NN; Wang HQ; Li SR; Gao X; Lin H; Su FC; Bu LL; Chen G; Liu B
J Dent Res; 2023 Feb; 102(2):178-186. PubMed ID: 36331313
[TBL] [Abstract][Full Text] [Related]
32. LOXL4 Shuttled by Tumor Cells-derived Extracellular Vesicles Promotes Immune Escape in Hepatocellular Carcinoma by Activating the STAT1/PD-L1 Axis.
Zhao L; Pei R; Ding Y; Su Z; Li D; Zhu S; Xu L; Zhao H; Zhou W
J Immunother; 2024 Feb-Mar 01; 47(2):64-76. PubMed ID: 38047403
[TBL] [Abstract][Full Text] [Related]
33. SUPREME-HN: a retrospective biomarker study assessing the prognostic value of PD-L1 expression in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck.
Pai SI; Cohen EEW; Lin D; Fountzilas G; Kim ES; Mehlhorn H; Baste N; Clayburgh D; Lipworth L; Resteghini C; Shara N; Fujii T; Zhang J; Stokes M; Wang H; Twumasi-Ankrah P; Wildsmith S; Khaliq A; Melillo G; Shire N
J Transl Med; 2019 Dec; 17(1):429. PubMed ID: 31878938
[TBL] [Abstract][Full Text] [Related]
34. USP39 Promotes the Viability and Migration of Head and Neck Squamous Cell Carcinoma Cell by Regulating STAT1.
Hu Y; Wang Y; Hu W; Hu C; Wang B; Liu C; Deng A; Shen B; Wu K; Liu Y
Technol Cancer Res Treat; 2024; 23():15330338241250298. PubMed ID: 38706215
[No Abstract] [Full Text] [Related]
35. Evaluation of programmed death ligand 1 expression in cytology to determine eligibility for immune checkpoint inhibitor therapy in patients with head and neck squamous cell carcinoma.
Liu Z; Williams M; Stewart J; Glisson BS; Fuller C; Roy-Chowdhuri S
Cancer Cytopathol; 2022 Feb; 130(2):110-119. PubMed ID: 34375025
[TBL] [Abstract][Full Text] [Related]
36. PD-L1 Influences Cell Spreading, Migration and Invasion in Head and Neck Cancer Cells.
Eichberger J; Schulz D; Pscheidl K; Fiedler M; Reichert TE; Bauer RJ; Ettl T
Int J Mol Sci; 2020 Oct; 21(21):. PubMed ID: 33138288
[TBL] [Abstract][Full Text] [Related]
37. Metastasis and immunosuppression promoted by mtDNA and PD-L1 in extracellular vesicles are reversed by WGP β-glucan in oral squamous cell carcinoma.
Ko HH; Peng HH; Cheng AN; Chou HE; Hou HH; Kuo WT; Liu WW; Kuo MY; Lee AY; Cheng SJ
Cancer Sci; 2023 Oct; 114(10):3857-3872. PubMed ID: 37525561
[TBL] [Abstract][Full Text] [Related]
38. The Evolving Landscape of PD-1/PD-L1 Pathway in Head and Neck Cancer.
Qiao XW; Jiang J; Pang X; Huang MC; Tang YJ; Liang XH; Tang YL
Front Immunol; 2020; 11():1721. PubMed ID: 33072064
[TBL] [Abstract][Full Text] [Related]
39. The transcription factor SpiB regulates the fibroblastic reticular cell network and CD8
Horsnell HL; Cao WH; Belz GT; Mueller SN; Alexandre YO
Immunol Cell Biol; 2024 Apr; 102(4):269-279. PubMed ID: 38441326
[TBL] [Abstract][Full Text] [Related]
40. CD4
Franken A; Bila M; Mechels A; Kint S; Van Dessel J; Pomella V; Vanuytven S; Philips G; Bricard O; Xiong J; Boeckx B; Hatse S; Van Brussel T; Schepers R; Van Aerde C; Geurs S; Vandecaveye V; Hauben E; Vander Poorten V; Verbandt S; Vandereyken K; Qian J; Tejpar S; Voet T; Clement PM; Lambrechts D
Immunity; 2024 Mar; 57(3):541-558.e7. PubMed ID: 38442708
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
